The factor VIII C1 domain contributes to platelet binding

Blood

Volumn 111, Issue 1, 2008, Pages 200-208

  Hsu, Ting Chang ^a   Pratt, Kathleen P ^a   Thompson, Arthur R ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b PUGET SOUND BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 8C; BLOOD CLOTTING FACTOR 8C1; FLUORESCEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C2; PHYCOERYTHRIN; STREPTAVIDIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ARTICLE; BINDING AFFINITY; BINDING SITE; CELL LABELING; CELL SURFACE; COMPLEX FORMATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MEMBRANE BINDING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION;

EID: 38049160762     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-01-068957     Document Type: Article

References (46)

1. Leyte A, Verbeet MP, Brodniewicz-Proba T, Van Mourik JA, Mertens K. The interaction between human blood-coagulation factor VIII and von Willebrand factor: characterization of a high-affinity binding site on factor VIII. Biochem J. 1989;257:679-683.
2. Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. A synthetic factor VIII peptide of eight amino acid residues (1677-1684) contains the binding region of an anti-factor VIII antibody which inhibits the binding of factor VIII to von Willebrand factor. Thromb Haemost. 1990;63:403-406.
3. Saenko EL, Scandella D. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor. J Biol Chem. 1997;272:18007-18014.
4. Rosing J, van Rijn JL, Bevers EM, van Dieijen G, Comfurius P, Zwaal RF. The role of activated human platelets in prothrombin and factor X activation. Blood. 1985;65:319-332.
5. Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost. 2005;31:381-392.
6. van Dieijen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem. 1981;256:3433-3442.
7. Duffy EJ, Lollar P. Intrinsic pathway activation of factor X and its activation peptide-deficient derivative, factor Xdes-143-191. J Biol Chem. 1992;267:7821-7827.
8. Gilbert GE, Arena AA. Activation of the factor VIIIa-factor IXa enzyme complex of blood coagulation by membranes containing phosphatidyl-L-serine. J Biol Chem. 1996;271:11120-11125.
9. Duffy EJ, Parker ET, Mutucumarana VP, Johnson AE, Lollar P. Binding of factor VIIIa and factor VIII to factor IXa on phospholipid vesicles. J Biol Chem. 1992;267:17006-17011.
10. Ahmad SS, Walsh PN. Role of the C2 domain of factor VIIIa in the assembly of factor-X activating complex on the platelet membrane. Biochemistry. 2005;44:13858-13865.
11. Pratt KP, Shen BW, Takeshima K, Davie EW, Fujikawa K, Stoddard BL. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature. 1999;402:439-442.
12. Gilbert GE, Kaufman RJ, Arena AA, Miao H, Pipe SW. Four hydrophobic amino acids of the factor VIII C2 domain are constituents of both the membrane-binding and von Willebrand factor-binding motifs. J Biol Chem. 2002;277:6374-6381.
13. Lewis DA, Pound ML, Ortel TL. Contributions of Asn2198, Met2199, and Phe2200 in the factor VIII C2 domain to cofactor activity, phospholipid-binding, and von Willebrand factor-binding. Thromb Haemost. 2003;89:795-802.
14. Saenko EL, Scandella D, Yakhyaev AV, Greco NJ. Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets. J Biol Chem. 1998;273:27918-27926.
15. Takeshima K, Smith C, Tait J, Fujikawa K. The preparation and phospholipid binding property of the C2 domain of human factor VIII. Thromb Haemost. 2003;89:788-794.
16. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82:70-77.
17. Pace CN, Vajdos F, Fee L, Grimsley G, Gray T. How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 1995;4:2411-2423.
18. Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature. 1984;312:337-342.
19. Ahmad SS, Scandura JM, Walsh PN. Structural and functional characterization of platelet receptor-mediated factor VIII binding. J Biol Chem. 2000;275:13071-13081.
20. Thompson AR, Chen SH. Characterization of factor IX defects in hemophilia B patients. Methods Enzymol. 1993;222:143-169.
21. Liu ML, Shen BW, Nakaya S, et al. Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure. Blood. 2000;96:979-987.
22. Fuentes-Prior P, Fujikawa K, Pratt KP. New insights into binding interfaces of coagulation factors V and VIII and their homologues lessons from high resolution crystal structures. Curr Protein Pept Sci. 2002;3:313-339.
23. Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia. 1998;4:558-563.
24. Peerlinck K, Jacquemin MG, Arnout J, et al. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. Blood. 1999;93:2267-2273.
25. Gilles JG, Lavend'homme R, Peerlinck K, et al. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes. Thromb Haemost. 1999;82:40-45.
26. Jacquemin M, Benhida A, Peerlinck K, et al. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood. 2000;95:156-163.
27. Lewis DA, Bovenschen N, Mertens K, Voorberg J, Ortel TL. Phospholipid vesicles interfere with the binding of antibody fragments to the light chain of factor VIII. Thromb Haemost. 2005;93:833-841.
28. Stoylova SS, Lenting PJ, Kemball-Cook G, Holzenburg A. Electron crystallography of human blood coagulation factor VIII bound to phospholipid monolayers. J Biol Chem. 1999;274:36573-36578.
29. Stoilova-McPhie S, Villoutreix BO, Mertens K, Kemball-Cook G, Holzenburg A. 3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography. Blood. 2002;99:1215-1223.
30. Adams TE, Hockin MF, Mann KG, Everse SJ. The crystal structure of activated protein C-inactivated bovine factor Va: Implications for cofactor function. Proc Natl Acad Sci U S A. 2004;101:8918-8923.
31. Ortel TL, Devore-Carter D, Quinn-Allen M, Kane WH. Deletion analysis of recombinant human factor V: evidence for a phosphatidylserine binding site in the second C-type domain. J Biol Chem. 1992;267:4189-4198.
32. Majumder R, Quinn-Allen MA, Kane WH, Lentz BR. The phosphatidylserine binding site of the factor Va C2 domain accounts for membrane binding but does not contribute to the assembly or activity of a human factor Xa-factor Va complex. Biochemistry. 2005;44:711-718.
33. Kalafatis M, Rand MD, Mann KG. Factor Vamembrane interaction is mediated by two regions located on the light chain of the cofactor. Biochemistry. 1994;33:486-493.
34. Saleh M, Peng W, Quinn-Allen MA, et al. The factor V C1 domain is involved in membrane binding: identification of functionally important amino acid residues within the C1 domain of factor V using alanine scanning mutagenesis. Thromb Haemost. 2004;91:16-27.
35. Scandella D, Gilbert GE, Shima M, et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood. 1995;86:1811-1819.
36. Li X, Gabriel DA. The physical exchange of factor VIII (FVIII) between von Willebrand factor and activated platelets and the effect of the FVIII B-domain on platelet binding. Biochemistry. 1997;36:10760-10767.
37. Phillips JE, Lord ST, Gilbert GE. Fibrin stimulates platelets to increase factor VIIIa binding site expression. J Thromb Haemost. 2004;2:1806-1815.
38. Nesheim ME, Pittman DD, Wang JH, Slonosky D, Giles AR, Kaufman RJ. The binding of 35S-labeled recombinant factor VIII to activated and unactivated human platelets. J Biol Chem. 1988;263:16467-16470.
39. Rawala-Sheikh R, Ahmad SS, Ashby B, Walsh PN. Kinetics of coagulation factor X activation by platelet-bound factor IXa. Biochemistry. 1990;29:2606-2611.
40. Tracy PB, Nesheim ME, Mann KG. Coordinate binding of factor Va and factor Xa to the unstimulated platelet. J Biol Chem. 1981;256:743-751.
41. Nesheim M, Pittman DD, Giles AR, et al. The effect of plasma von Willebrand factor on the binding of human factor VIII to thrombin-activated human platelets. J Biol Chem. 1991;266:17815-17820.
42. Soberano ME, Clarke D, Zucker MB. Binding of thrombin-activated human factor VIII to platelets. Br J Haematol. 1986;64:571-585.
43. Panteleev MA, Ananyeva NM, Greco NJ, Ataullakhanov FI, Saenko EL. Two subpopulations of thrombin-activated platelets differ in their binding of the components of the intrinsic factor X-activating complex. J Thromb Haemost. 2005;3:2545-2553.
44. Perret BA, Furlan M, Beck EA. Binding of bovine factor VIII-coated colloidal gold particles to receptors on platelet membranes. Agents Actions. 1981;11:657-659.
45. Kempton CL, Hoffman M, Roberts HR, Monroe DM. Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations. Arterioscler Thromb Vasc Biol. 2005;25:861-866.
46. Brinkman HJ, Mertens K, van Mourik JA. Phospholipid-binding domain of factor VIII is involved in endothelial cell-mediated activation of factor X by factor IXa. Arterioscler Thromb Vasc Biol. 2002;22:511-516.